Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion description "[In addition to the higher risk for exudative AMD in patients with the CFH 402HH genotype that was found in previous studies, our results show that the CFH 402HH genotype also correlates with lower visual acuity outcome after treatment with bevacizumab, suggesting that pharmacogenetics of CFH plays a role in response to treatment of wet AMD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion evidence source_evidence_literature NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion SIO_000772 21232084 NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion wasDerivedFrom befree-2016 NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion wasGeneratedBy ECO_0000203 NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- befree-2016 importedOn "2016-02-19" NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.